BioSpace News Archive

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., Chief Executive Officer and Co-founder, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019, at 9:50 a.m. EST.

Surface Oncology announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D., chief scientific officer, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference.

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, announced that that it has engaged Kilmer Lucas Inc. to provide the Company with select U.S. and Canadian investor relations and strategic advisory services..

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, announced that it will participate in the Piper Jaffray 31st Annual Healthcare Conference in New York, NY.

Presentations will highlight the potential for oral SPR994 to change the treatment landscape in cUTI and the opportunity for oral SPR720 in NTM

First Product Developed from Spatial Transcriptomics Acquisition

Previously, Toujeo was approved only for adults aged 18 years and older.

Bio Buzz selected five women venture capitalists who are considered “trailblazing investors shaping the future of life science investing” in the BioCapital Hotbed Community, which includes Delaware, Maryland, Virginia and Washington, D.C.

Eisai Co., Ltd. has announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States.

Liminal BioSciences Inc. has announced that it has closed on the previously announced divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. (“PBL”) to KKR & Co., a leading global investment firm (“KKR”).